Is Gland Pharma Overvalued or Undervalued Right Now?
- September 1, 2026
- Posted by: Kunal Singla
- Category: Market
Gland Pharma CMP Rs 2,894.00 (31 Aug 2026), up 0.21%. PE 42.18 vs industry PE 38.07. ROE 9.92%. 52W range Rs 1,573.60 to Rs 3,039.80.
Quick Answer
Gland Pharma trades at a price to earnings ratio of 42.18 against an industry average of 38.07, which puts the stock close to fair value on a simple multiple basis rather than clearly overvalued or undervalued. The company’s 9.92% return on equity and Rs 627.88 book value per share fit broadly within its sector’s range. Whether Gland Pharma is overvalued or undervalued right now is less about a wide valuation gap and more about how its growth and margins evolve from here.
Is Gland Pharma overvalued or undervalued right now is a question worth asking given how its price to earnings ratio compares with the rest of its sector. At the current market price of Rs 2,894.00, the stock trades roughly 4.8% below its 52 week high of Rs 3,039.80 and about 83.9% above its 52 week low of Rs 1,573.60.
Gland Pharma’s share price moved up 0.21% in Monday’s session to Rs 2,894.00, against a market capitalisation of Rs 47,610 Cr. This article looks at the numbers, the PE ratio, price to book, return on equity, debt levels and recent earnings trends, that determine whether the current price reflects fair value or a stretched multiple.
Click Here – Get Free Investment Predictions
Gland Pharma Valuation Metrics: Where Does the Stock Stand?
| Valuation Metric | Gland Pharma |
|---|---|
| CMP (31 Aug 2026) | Rs 2,894.00 |
| Market Cap | Rs 47,610 Cr |
| P/E Ratio | 42.18 |
| Industry P/E | 38.07 |
| P/B Ratio | 4.60 |
| Sector Average P/B (pharmaceutical) | 7.31 |
| Return on Equity (ROE) | 9.92% |
| Sector Average ROE (pharmaceutical) | 12.94% |
| EPS (TTM) | Rs 68.43 |
| Book Value per Share | Rs 627.88 |
| Debt to Equity | 0.03 |
| Dividend Yield | 0.69% |
| Sector Average Dividend Yield (pharmaceutical) | 0.30% |
| 52 Week High / Low | Rs 3,039.80 / Rs 1,573.60 |
The headline number here is the price to earnings ratio. At 42.18, the Gland Pharma PE ratio is 1.11 times the industry average of 38.07. Measured against its pharmaceutical sector peers, the gap widens further on other measures too: a P/B of 4.60 against a sector average of 7.31, and an ROE of 9.92% against a sector average of 12.94%.
Is Gland Pharma Overvalued Based on Its P/E Ratio?
Based on the P/E ratio alone, Gland Pharma looks fairly valued. The stock’s PE of 42.18 sits close to the industry average of 38.07, which suggests the market is pricing the business roughly in line with its sector rather than at a premium or a discount. That leaves the read on whether Gland Pharma is overvalued or undervalued more dependent on its growth trajectory than on the PE ratio itself.
Check Gland Pharma’s Live Fundamentals on the Univest Screener
Gland Pharma’s Financial Growth and Profitability
Gland Pharma’s revenue moved from Rs 5,830.11 crore in FY2025 to Rs 6,746.98 crore in FY2026, a change of 15.7%. Net profit grew from Rs 698.53 crore to Rs 1,027.32 crore over the same period, a swing of roughly 47.1%.
The Gland Pharma share price has moved alongside this earnings trend, which is part of why the stock now trades at 1.11 times the industry PE of 38.07 rather than a flat multiple.
Download the Univest iOS App or Univest Android App to track Gland Pharma’s live share price and valuation ratios.
Arguments That Gland Pharma Could Be Overvalued
- Sector-wide re-rating risk: If sentiment toward the sector turns, a PE of 42.18 still has room to compress toward the industry average of 38.07.
- Limited margin of safety: At Rs 2,894.00, the stock is only 4.8% below its 52 week high of Rs 3,039.80, leaving less room for error if earnings disappoint.
Arguments That Support the Premium Valuation
- Low leverage: A debt to equity ratio of 0.03 gives Gland Pharma a comparatively strong balance sheet.
- 52 week range context: At Rs 2,894.00, the stock is 83.9% above its 52 week low of Rs 1,573.60, showing it has already found some support at lower levels.
Verdict: Is Gland Pharma Overvalued or Undervalued Right Now?
On balance, Gland Pharma looks fairly valued rather than clearly overvalued or undervalued. Its PE of 42.18 sits close to the industry average of 38.07, and its 9.92% ROE and other ratios do not point to a significant mispricing either way. The more useful question for investors from here is less about the current multiple and more about whether earnings growth accelerates or slows.
What Could Change This Valuation Picture for Gland Pharma?
Two broad scenarios could shift this valuation call on Gland Pharma in either direction. On the upside, an improvement in return ratios or growth that pushes the stock’s PE of 42.18 toward a premium over the industry average of 38.07. On the downside, a deterioration in the numbers that pulls the PE below the industry average of 38.07 instead. Investors watching the Gland Pharma share price over the next few quarters should track whether reported ROE holds near 9.92% and whether the PE gap versus the industry average of 38.07 widens or narrows, since both will matter more to the eventual answer than the current price point on its own.
Conclusion
Gland Pharma’s numbers point to a stock that is fairly valued on headline multiples. Investors tracking the Gland Pharma share price should watch whether earnings growth can keep pace with the current PE of 42.18, since that gap remains the single biggest variable in whether the stock is undervalued, fairly priced, or overvalued from here. This article is for informational purposes only and is not investment advice.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
FAQs on Gland Pharma Valuation
Is Gland Pharma overvalued or undervalued right now?
Ans. Based on a PE ratio of 42.18 against an industry average of 38.07, Gland Pharma currently looks fairly valued on relative valuation. Its 9.92% ROE is an important part of the picture alongside the PE ratio.
What is Gland Pharma’s current PE ratio?
Ans. Gland Pharma’s price to earnings ratio stands at 42.18, compared with an industry average PE of 38.07.
What is Gland Pharma’s return on equity?
Ans. Gland Pharma generates a return on equity of 9.92%, against a sector average of 12.94% among pharmaceutical peers.
What is Gland Pharma’s 52 week high and low?
Ans. Gland Pharma’s 52 week high is Rs 3,039.80 and its 52 week low is Rs 1,573.60. The stock currently trades around Rs 2,894.00, roughly 4.8% below its high.
Does Gland Pharma have high debt?
Ans. Gland Pharma carries a debt to equity ratio of 0.03, which is low for its sector.
What is Gland Pharma’s dividend yield?
Ans. Gland Pharma offers a dividend yield of 0.69% at the current share price.
Is Gland Pharma a good stock to buy at current levels?
Ans. Gland Pharma’s current valuation suits investors who agree with the fairly valued read on its PE ratio and are comfortable with the trade-off between its return ratios and its price. This is for informational purposes only and is not investment advice.
What is Gland Pharma’s price to book ratio?
Ans. Gland Pharma trades at a price to book ratio of 4.60, compared with a sector average of 7.31 among pharmaceutical peers.
